Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH lifted its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 50.4% during the second quarter, HoldingsChannel.com reports. The firm owned 124,857 shares of the company’s stock after purchasing an additional 41,857 shares during the period. Trust Co. of Toledo NA OH’s holdings in Trevi Therapeutics were worth $298,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in Trevi Therapeutics by 7.6% in the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company’s stock valued at $336,000 after acquiring an additional 10,780 shares during the last quarter. State Street Corp acquired a new stake in Trevi Therapeutics in the 1st quarter valued at about $81,000. Virtu Financial LLC acquired a new stake in Trevi Therapeutics in the 1st quarter valued at about $44,000. FMR LLC acquired a new stake in Trevi Therapeutics in the 2nd quarter valued at about $234,000. Finally, Northern Trust Corp grew its stake in Trevi Therapeutics by 305.6% in the 2nd quarter. Northern Trust Corp now owns 46,298 shares of the company’s stock valued at $130,000 after acquiring an additional 34,884 shares during the last quarter. 76.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research note on Friday, August 11th.

Trevi Therapeutics Stock Performance

NASDAQ:TRVI opened at $2.35 on Friday. The company’s 50-day moving average is $2.27 and its two-hundred day moving average is $2.33. Trevi Therapeutics, Inc. has a 12-month low of $1.43 and a 12-month high of $3.50.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Analysts forecast that Trevi Therapeutics, Inc. will post -0.33 earnings per share for the current fiscal year.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.